Skip to main content
. 2022 Nov 21;54(12):1786–1794. doi: 10.1038/s41588-022-01208-7

Table 3.

Mega-analysis: carrier frequency, effect sizes, median age at onset and attributable fraction

Mega-analysis Carrier frequency OR (95% CI) Median age at onset (IQR) Attributable fraction
Gene Group No. variant/no. carriers EOAD/LOAD/controls, % Case/control EOAD/control LOAD/control EOAD/LOAD, %
Primary analysis SORL1 LOF+REVEL50 212/418 2.75/1.51/0.68 2.5 (2.0–3.0) 3.3 (2.6–4.1) 2.0 (1.6–2.5) 65 (59–73) 1.91/0.75
—Missense (REVEL 50–100) 161/354 2.02/1.31/0.66 2.1 (1.7–2.5) 2.5 (2.0–3.2) 1.8 (1.4–2.3) 67 (59–74) 1.22/0.58
—LOF 51/68 0.78/0.21/0.02 19.8 (11.9–32.7) 40.7 (12.5–133) 11.3 (3.3–38.3) 62 (56–69) 0.76/0.19
TREM2 LOF+REVEL25 26/441 2.27/1.90/0.75 2.8 (2.3–3.5) 3.3 (2.6–4.3) 2.6 (2.1–3.3) 69 (62–75) 1.58/1.17
LOF+REVEL25 (refined) 25/404 2.22/1.77/0.62 3.1 (2.6–3.8) 3.8 (2.9–4.9) 2.8 (2.2–3.6) 68 (62–75) 1.63/1.15
—Missense (REVEL 25–100) 14/377 2.06/1.63/0.59 3.0 (2.5–3.8) 3.7 (2.8–4.9) 2.7 (2.1–3.6) 68 (62–75) 1.50/1.04
—LOF 12/66 0.21/0.29/0.16 2.1 (1.2–3.4) 1.7 (0.8–3.5) 2.2 (1.3–3.9) 71 (63–76) 0.09/0.16
—LOF (refined) 11/29 0.16/0.16/0.02 5.6 (2.6–12.1) 5.8 (1.7–19) 5.4 (1.8–16.8) 71 (63–74) 0.13/0.13
ABCA7 LOF+REVEL25 351/1,489 6.18/5.04/3.90 1.4 (1.3–1.6) 1.6 (1.4–1.9) 1.3 (1.2–1.5) 69 (61–78) 2.40/1.29
—Missense (REVEL 25–100) 302/1,372 5.58/4.65/3.63 1.4 (1.3–1.6) 1.6 (1.4–1.8) 1.3 (1.2–1.5) 69 (62–78) 2.06/1.18
—LOF 49/119 0.62/0.39/0.27 1.7 (1.1–2.4) 2.2 (1.4–3.5) 1.4 (0.9–2.1) 67 (57–74) 0.34/0.11
ATP8B4 LOF+REVEL25 94/850 3.56/3.08/2.09 1.4 (1.2–1.6) 1.5 (1.3–1.8) 1.4 (1.2–1.6) 70 (61–78) 1.24/0.84
—Missense (REVEL 25–100) 74/797 3.35/2.93/1.93 1.5 (1.3–1.7) 1.6 (1.3–1.9) 1.4 (1.2–1.7) 70 (62–78) 1.20/0.84
—LOF 20/54 0.21/0.16/0.16 1.1 (0.6–1.9) 1.2 (0.6–2.4) 1.0 (0.5–1.8) 70 (59–78) 0.03/−0.01
ABCA1 LOF+REVEL75 122/442 1.91/1.50/1.13 1.6 (1.3–2.0) 1.9 (1.5–2.5) 1.5 (1.2–1.9) 70 (60–76) 0.91/0.48
LOF+REVEL75 (refined) 120/282 1.52/1.10/0.52 2.4 (1.9–3.1) 2.9 (2.2–4.0) 2.2 (1.6–2.9) 70 (59–76) 1.01/0.60
—Missense (REVEL 75–100) 95/395 1.63/1.32/1.05 1.5 (1.2–1.8) 1.7 (1.3–2.2) 1.4 (1.1–1.8) 70 (61–76) 0.68/0.37
—Missense (REVEL 75–100 (refined)) 93/235 1.24/0.92/0.44 2.3 (1.7–3.0) 2.7 (1.9–3.8) 2.1 (1.5–2.8) 70 (59–76) 0.78/0.48
—LOF 27/47 0.28/0.18/0.08 3.5 (1.9–6.4) 4.7 (2.2–10.3) 2.8 (1.3–6.1) 67 (59–77) 0.22/0.11
ADAM10 LOF + REVEL ≥ 50 19/22 0.23/0.05/0.02 4.7 (2.0–10.8) 9.0 (2.9–28) 2.2 (0.5–8.2) 63 (60–68) 0.20/0.03
GWAS-targeted analysis RIN3 LOF+REVEL50 23/583 2.67/2.10/1.62 1.4 (1.2–1.7) 1.6 (1.3–2.0) 1.3 (1.1–1.6) 70 (59–79) 1.04/0.46
—Missense (REVEL 50–100) 17/577 2.62/2.08/1.61 1.4 (1.2–1.7) 1.6 (1.3–2.0) 1.3 (1.1–1.6) 70 (59–79) 1.01/0.45
—LOF 6/8 0.06/0.03/0.01 2.1 (0.5–9.3) 2.9 (0.5–18.0) 1.7 (0.3–10.3) 69 (57–86) 0.04/0.01
CLU LOF+REVEL25 24/26 0.23/0.09/0.03 3.6 (1.6–8.3) 5.8 (2.0–17.1) 2.5 (0.8–7.6) 63 (58–73) 0.19/0.05
—Missense (REVEL 25–100) 14/16 0.12/0.06/0.03 2.6 (0.9–7.5) 3.6 (0.9–13.6) 2.1 (0.6–8.0) 68 (58–76) 0.08/0.03
—LOF 10/10 0.12/0.03/0.01 7.3 (1.9–27.2) 14.2 (2.9–470.4) 3.8 (0.6–122.4) 63 (59–68) 0.11/0.02
ZCWPW1 LOF 11/15 0.15/0.05/0.01 5.0 (1.9–13.5) 9.1 (2.0–42.0) 2.9 (0.8–14.7) 63 (58–81) 0.14/0.03
ACE LOF+REVEL75 38/99 0.60/0.39/0.20 2.0 (1.3–2.9) 2.4 (1.5–4.1) 1.7 (1.0–2.7) 67 (60–75) 0.35/0.16
—Missense (REVEL 75–100) 10/49 0.33/0.22/0.07 3.2 (1.7–5.7) 3.9 (1.8–8.8) 2.7 (1.3–5.9) 66 (61–72) 0.24/0.14
—LOF 28/50 0.27/0.16/0.14 1.4 (0.8–2.4) 1.7 (0.9–3.4) 1.2 (0.6–2.2) 70 (55–76) 0.11/0.02

For each gene, the AD association statistics are shown for the variant deleteriousness threshold with the most evidence for AD association in the meta-analysis (bold). For genes with sufficient carriers, signals are shown for LOF and missense variants separately (regular text). Individual variants contributing to the burden were validated in a multistage analysis (Supplementary Table 16 and Methods), which resulted in the construction of a refined burden for TREM2 (one variant removed) and ABCA1 (two variants removed). The attributable fraction of a gene is an estimate of the fraction of EOAD and LOAD cases in this sample that have become part of this dataset due to carrying a rare damaging variant in the respective gene (Methods). Note that several variants were excluded from this analysis (that is, due to differential missingness) that would otherwise have been included in the burden. See section 2 of the Supplementary Note for a gene-specific discussion of the variants that contribute to the association with AD and Supplementary Data for the list of variants considered in the burden analysis. Genes shown in bold: the variant burden was significantly associated with AD in the meta-analysis (Holm–Bonferroni <0.05; Table 1). P values for the mega-analysis are shown in Supplementary Table 15.